BRPI0914734A2 - assinaturas e determinantes associados com metástase e métodos de uso dos mesmos - Google Patents

assinaturas e determinantes associados com metástase e métodos de uso dos mesmos

Info

Publication number
BRPI0914734A2
BRPI0914734A2 BRPI0914734A BRPI0914734A BRPI0914734A2 BR PI0914734 A2 BRPI0914734 A2 BR PI0914734A2 BR PI0914734 A BRPI0914734 A BR PI0914734A BR PI0914734 A BRPI0914734 A BR PI0914734A BR PI0914734 A2 BRPI0914734 A2 BR PI0914734A2
Authority
BR
Brazil
Prior art keywords
signatures
metastasis
methods
determinants associated
determinants
Prior art date
Application number
BRPI0914734A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenneth L Scott
Lynda Chin
Papia Ghosh
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BRPI0914734A2 publication Critical patent/BRPI0914734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914734A 2008-06-26 2009-06-26 assinaturas e determinantes associados com metástase e métodos de uso dos mesmos BRPI0914734A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
PCT/US2009/048862 WO2009158620A2 (en) 2008-06-26 2009-06-26 Signatures and determinants associated with metastasis methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0914734A2 true BRPI0914734A2 (pt) 2015-10-20

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914734A BRPI0914734A2 (pt) 2008-06-26 2009-06-26 assinaturas e determinantes associados com metástase e métodos de uso dos mesmos

Country Status (14)

Country Link
US (1) US20110182881A1 (enExample)
EP (1) EP2307886A2 (enExample)
JP (1) JP2011526693A (enExample)
KR (1) KR20110036056A (enExample)
CN (1) CN102132160A (enExample)
AU (1) AU2009262022A1 (enExample)
BR (1) BRPI0914734A2 (enExample)
CA (1) CA2728674A1 (enExample)
IL (1) IL210245A0 (enExample)
MX (1) MX2010014280A (enExample)
NZ (1) NZ590385A (enExample)
RU (1) RU2011102743A (enExample)
WO (1) WO2009158620A2 (enExample)
ZA (1) ZA201100225B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
AU2011216404B2 (en) 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8880457B2 (en) * 2010-11-05 2014-11-04 Allegheny-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
US9719937B2 (en) 2011-05-11 2017-08-01 Todos Medical Ltd. Diagnosis of cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
CN103842813B (zh) * 2011-09-06 2018-04-17 贝克顿·迪金森公司 用于对样品中的稀少目标细胞进行细胞计数检测的方法和组合物
WO2014036470A1 (en) 2012-08-31 2014-03-06 Sloan-Kettering Institute For Cancer Research Particles, methods and uses thereof
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP6465811B2 (ja) 2012-12-19 2019-02-06 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多様式の粒子、方法およびその使用
AU2014218867B2 (en) 2013-02-20 2018-11-08 Sloan-Kettering Institute For Cancer Research Wide field raman imaging apparatus and associated methods
EP4265740A3 (en) * 2013-03-14 2024-04-24 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
EP3004870B1 (en) 2013-05-28 2019-01-02 Todos Medical Ltd. Differential diagnosis of benign tumors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
US20150252434A1 (en) * 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016018896A1 (en) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
US11009467B2 (en) * 2015-02-17 2021-05-18 Siemens Healthcare Diagnostics Inc. Model-based methods and apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
WO2017004301A1 (en) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
CN109844140A (zh) * 2016-10-28 2019-06-04 茂英基因科技股份有限公司 辨识转移性肿瘤的原发位置的方法及系统
US20200224277A1 (en) * 2017-07-17 2020-07-16 Mao Ying Genetech Inc. Cell type identification method and system thereof
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
CA3233047A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
AU2022405276A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) * 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
WO2003025141A2 (en) * 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
US20050208500A1 (en) * 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
EP1751306A1 (en) * 2004-04-30 2007-02-14 Yale University Methods and compositions for cancer diagnosis
JP5184087B2 (ja) * 2004-09-22 2013-04-17 トリパス イメージング， インコーポレイテッド ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090069196A1 (en) * 2006-03-22 2009-03-12 Mathias Gehrmann Prediction of Breast Cancer Response to Chemotherapy
NZ575090A (en) * 2006-09-06 2012-02-24 Univ California Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20110160072A1 (en) * 2007-10-23 2011-06-30 Clinical Genomics Pty. Ltd. Method of diagnosing neoplasms
NZ587903A (en) * 2008-02-14 2013-05-31 Decode Genetics Ehf Susceptibility for lung cancer using the polymorphic marker rs1051730
WO2009124251A1 (en) * 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
CA2724348A1 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
EP2307886A2 (en) 2011-04-13
MX2010014280A (es) 2011-05-23
KR20110036056A (ko) 2011-04-06
RU2011102743A (ru) 2012-08-10
JP2011526693A (ja) 2011-10-13
WO2009158620A2 (en) 2009-12-30
CA2728674A1 (en) 2009-12-30
IL210245A0 (en) 2011-03-31
ZA201100225B (en) 2011-10-26
US20110182881A1 (en) 2011-07-28
WO2009158620A3 (en) 2010-06-03
NZ590385A (en) 2012-11-30
AU2009262022A1 (en) 2009-12-30
CN102132160A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
BRPI0914734A2 (pt) assinaturas e determinantes associados com metástase e métodos de uso dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BR112012024120A2 (pt) sarms e método de uso dos mesmos
BRPI0916229A2 (pt) assinaturas e determinantes pcs associados com câncer de próstata e métodos de utilização dos mesmos
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0822229A2 (pt) Coacervados de complexos adesivo e métodos de fabricação e uso dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI1009413A2 (pt) emulsões e adesivos contendo proteína e produção e uso dos mesmos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0921983A2 (pt) moduladores tgr5 e métodos de uso dos mesmos
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
EP2240973A4 (en) POROUS ELECTRODES AND CORRESPONDING METHODS
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BRPI0921569A2 (pt) anticorpos para il-6 e uso dos mesmos
EP2344481A4 (en) VIRUS AND FUNGI
DK2300609T3 (da) Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf
BRPI0817614A2 (pt) particulados geradores de eletricidade e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25H Request for change of headquarter rejected

Owner name: DANA-FARBER CANCER INSTITUTE INC. (US)